New mRNA shingles vaccine enters human testing
NCT ID NCT07285265
First seen Dec 26, 2025 · Last updated May 15, 2026 · Updated 18 times
Summary
This early-stage trial tests a new mRNA vaccine (ABO1108) for shingles in 180 healthy adults aged 40 and older. Participants receive two shots about two months apart at different dose levels. The study focuses on safety and how well the vaccine triggers an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VARICELLA-ZOSTER VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rongshui Miao Autonomous County Center for Disease Control and Prevention
Liuzhou, Rongshui, China
Conditions
Explore the condition pages connected to this study.